My Treatment Approach: Optimizing Treatment for Chronic GVHD - Episode 12

Clinical Impact of Patient-Reported Outcomes in cGVHD

,

Medical experts discuss the role of patient-reported outcomes in cGVHD.

Video content above is prompted by the following:

  • What is the role of patient-reported outcomes (PROs) to measure symptom burden, adverse effect burden, and quality of life and treatment response in cGVHD in your practice?

Which PRO measures are most useful for evaluating disease improvement in cGVHD?

  • What do results from recently published PRO data for belumosudil show (Lee SJ, et al. Transplant Cell Ther. 2022)?

Also summarize data with ruxolitinib (Zeiser R, et al. N Engl J Med. 2021) and FDA analysis of ibrutinib PRO data (King-Kallimanis BL, et al. Qual Lif Res. 2020).

  • How can available PRO data be utilized in clinical practice to improve quality of life of patients with cGVHD?